Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: A 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia

Clinical Therapeutics

Volumn 30, Issue 3, 2008, Pages 528-534

  Uygun, Ahmet ^a   Kadayifci, Abdurrahman ^b   Yesilova, Zeki ^a   Safali, Mukerrem ^a   Ilgan, Seyfettin ^a   Karaeren, Necmettin ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

eradication; Helicobacter pylori; nonulcer dyspepsia; sequential treatment

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PANTOPRAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPEPSIA; ENDOSCOPY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SMOKING; THORAX PAIN; UREA BREATH TEST; VAGINAL PRURITUS; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TETRACYCLINE; TREATMENT OUTCOME;

EID: 41649117291     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.03.009     Document Type: Article

References (37)

1. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 56 (2007) 772-781
2. Lam S., and Talley N. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13 (1998) 1-12
3. for the Canadian Helicobacter Study Group. Bourke B., Ceponis P., Chiba N., et al. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents an evidence-based evaluation. Can J Gastroenterol. 19 (2005) 478
4. Can J Gastroenterol. 19 (2005) 399-408
5. Malfertheiner P., Bayerdörffer E., Diete U., et al. The GU-MACH study: The effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 13 (1999) 703-712
6. Zanten S., Bradette M., Farley A., et al. The DU-MACH study: Eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 13 (1999) 289-295
7. Gisbert J., Khorrami S., Calvet X., and Pajares J. Pantoprazole based therapies in Helicobacter pylori eradication: A systemic review and meta-analysis. Eur J Gastroenterol Hepatol 16 (2004) 89-99
8. Farup P., Tholfsen J., Wetternus S., et al. Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Scand J Gastroenterol 37 (2002) 1374-1379
9. Kadayifci A., Simsek H., and Tatar G. The efficiency of omeprazole and dual antibiotic treatment schemes for H pylori eradication. Turk J Gastroenterol 7 (1996) 228-232
10. Uygun A., Ates Y., Erdil A., et al. Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. Clin Ther 21 (1999) 1539-1548
11. Neri M., Milano A., Laterza F., et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 18 (2003) 821-827
12. Wermeille J., Cunningham M., Dederding J.P., et al. Failure of Helicobacter pylori eradication: Is poor compliance the main cause?. Gastroenterol Clin Biol. 26 (2002) 207-209
13. Calvet X., Ducons J., Bujanda L., et al., For the Asociación Española de Gastroenterología. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: A multicenter randomized trial. Am J Gastroenterol 100 (2005) 1696-1701
14. Sivri B., Simsek I., Hulagu S., et al. The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H pylori eradication and duodenal ulcer healing. Curr Med Res Opin 20 (2004) 1301-1307
15. Uygun A., Kadayifci A., Yesilova Z., et al. Recent success of pantoprazole- or lansoprazole-based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. Turk J Gastroenterol 15 (2004) 219-224
16. Kadayifci A., Buyukhatipoglu H., Cemil S.M., and Simsek I. Eradication of Helicobacter pylori with triple therapy: An epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 11 (2006) 1960-1966
17. Huang J.Q., and Hunt R.H. Treatment ater failure: The problem of "nonresponders.". Gut. 45 Suppl1 (1999) 140-144
18. Zullo A., Vaira D., Vakil N., et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther. 17 (2003) 1205-1726
19. Aliment Pharmacol Ther. 17 (2003) 719
20. Hassan C., De Francesco V., Zullo A., et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: Improving the cost of pharmacotherapy. Aliment Pharmacol Ther 18 (2003) 641-646
21. De Francesco V., Zullo A., Margiotta M., et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 19 (2004) 407-414
22. Vaira D., Zullo A., Vakil N., et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized trial. Ann Intern Med 146 (2007) 556-563
23. (February 22, 2008). http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf
24. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Canary Wharf, UK: EMEA; 2002.
25. Salako S. The Declaration of Helsinki 2000: Ethical principles and the dignity of difference. Med Law 25 (2006) 341-354
26. Dixon M.F., Genta R.M., Yardley J.H., and Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20 (1996) 1161-1181
27. (December 27, 2007). http://interactive.snm.org/docs/pg_ch07_0403.pdf
28. Balon H.R., Roff E., Freitas J.E., et al. al.: Society of Nuclear Medicine (SNM) Procedure Guideline for C-14 Urea bacter Breath Test: Version 3.0, approved from June 23, 2001 [SNM Web site].
29. 14C-urea breath test for the diagnosis of Helicobacter pylori infection: Clinical validation and comparison with the standard method. Eur J Nucl Med Mol Imaging 30 (2003) 1457-1462
30. Dawson B., and Trapp R.G. Basic & Clinical Biostatistics. 4th ed. (2004), McGraw-Hill Companies, New York, NY
31. Perri F., Villani M.R., Festa V., et al. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy.'. Aliment Pharmacol Ther. 15 (2001) 1023-1029
32. Gisbert J., and Pajares J. Helicobacter pylori therapy: First-line options and rescue regimen. Dig Dis 19 (2001) 134-143
33. Huang J., Zheng G., Hunt R., et al. Do patients with non-ulcer dyspepsia respond differently to Helico-pylori eradication treatments those with peptic ulcer disease? A systematic review. World J Gastroenterol 11 (2005) 2726-2732
34. Mégraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 64 (2004) 1893-1904
35. Simsek H., Balaban Y., Gunes D., et al. Alarming clarithromycin resistance of Helicobacter pylori in Turkish population. Helicobacter 10 (2005) 360-361
36. Can F., Demirbilek M., Selçuk H., et al. Clarithromycin resistance of Helicobacter pylori strains isolated from antral biopsy specimens [in Turkish]. Mikrobiyol Bul 38 (2004) 349-353
37. Moshkowitz M., Konikoff F., Peled Y., et al. High Helicobacter pylori numbers are associated with low eradication rate after triple. Gut 36 (1995) 845-847